Dr. Ge’s research focuses on using clinical informatics, data science and artificial intelligence to improve the quality of care for patients with advanced liver diseases and awaiting transplant.
Dr. Gennatas has developed rtemis, a comprehensive data science platform, which supports advanced visualization, statistical analyses, and machine learning. It provides both a highly flexible and efficient API as well as a no-code web application to bring advanced data science tools to biomedical researchers and clinicians regardless of technical expertise.
This project aims to improve the throughput by automated rapid scanning with minimal input from technicians and improve patient comfortableness with an ECG-free and free-breathing scan procedure with self-navigation powered by an inline AI framework.
Dr. Rauschecker’s lab leverages modern AI methodologies to quantify, describe, and understand clinical brain MRIs. This work includes new imaging biomarker discovery, using AI for diagnostics and prognostics, and using AI for better understanding variation in the normal brain.
Dr. Semere is using machine learning and novel computational linguistics techniques to characterize secure message communication between racially/ethnically diverse patients with diabetes, their caregivers, and providers. She is applying this information to develop family-centered technology based communication strategies that promote effective diabetes management.
Dr. Feng has developed machine learning and deep learning algorithms that accurately quantify their uncertainty and are appropriate for high dimensional datasets. Her current research is in developing safe machine learning algorithms that learn and recalibrate using streaming Electronic Health Records data.
Dr. Sarkar’s research focuses on: (1) Ambulatory patient safety, (2) Digital health innovations to improve the safety and quality of outpatient care, (3) Social media research for behavior change, (4) Safety-net implementation of evidence-based digital health in real-world settings.
Dr. Hswen current research seeks to identify authentic attitudes, feelings and beliefs that influence behaviors and drive populations. Through the collection of unconventional and underground online social networks, Dr. Hswen captures unfiltered conversations to further understand the connections between social experiences and health.
Pathology and laboratory medicine provide 70% of the information in most patient care settings. Therefore, using the best software is the best way to deliver that information to the clinicians on the front lines. I am interested in developing these software solutions by utilizing the best practices from the cutting edge artificial intelligence technologies to traditional methods.
Dr. Scheffler develops statistical methods for high-dimensional signals produced by his collaborators in neurology and orthopedics. The proper interrogation of this data will lead to improved health outcomes at both the patient and population level.
We are developing & testing smartphone apps that use reinforcement learning models to personalize text-messages to encourage physical activity. The apps are designed for English & Spanish speaking individuals diagnosed with depression and diabetes, being treated at the ZSFGH.
Dr. Rankin investigates the underpinnings of human socioemotional behavior in aging and neurodegenerative disease with quantitative brain imaging, and develops tools for harmonizing cross-disciplinary data and analytic processes to facilitate scientific collaboration and clinical care.
Dr. Murray is leading the Advanced Analytics & Innovation team, she is involved in large analytic projects using EHR data to inform quality and value improvement efforts at the medical center. She is interested in predictive analytics and has done research in EHR phenotyping.
Sanders Lab aims to identify the etiology of developmental disorders through the discovery of genetic risk factors. They aim to continue progress, leverage findings to build a complete understanding of ASD, & extend this approach to other human disorders, including congenital malformations.
Dr. Hong’s research program focuses on combining clinical domain knowledge with data science to generate insights from real world data, develop actionable computational tools, and evaluate the benefit of these advances in personalized cancer care.
Dr. Whooley’s work focuses on applying the methods of health services research (including data science, implementation science, and program evaluation) to accelerate the adoption of evidence-based practices within the context of a national learning healthcare system. One of her specific interest areas is in the domain of cardiovascular health outcomes.
Dr. Pirracchio focuses on three clinical research areas including evaluation and optimization of daily cares in the intensive care unit. He is also broadly interested in problems of causal inference and prediction, particularly developing novel methodologies for addressing scientific questions using complex observational data subject to sampling biases.
Dr. Seo applies his expertise in radionuclide and x-ray imaging physics and instrumentation to develop quantitative imaging techniques for everything from small animal research to analysis of clinical research data.
Dr. Pedoia develops analytics to model the complex interactions between morphological, biochemical and biomechanical aspects of the knee joint as a whole; deep learning convolutional neural network for musculoskeletal tissue segmentation and for the extraction of silent features from quantitative relaxation maps for a comprehensive study of the biochemical articular cartilage composition; with ultimate goal of developing a completely data-driven model that is able to extract imaging features and use them to identify risk factors and predict outcomes for Osteoarthritis.
Dr. Goldstien uses the tools of big data, statistics and machine learning to answer questions related to Precision Medicine such as: How can we learn from the inventory of genomic test and knowledge in the EMR about patient outcomes and the data associated with individual patients to better direct their care? How can we better use repeatable animal models to translate knowledge to human patients? How can we integrate existing knowledge and high throughput data? Can we use genomic data to bring new therapies to bear?
The Zaitlen lab develops statistical and computational tools to discover the genetic basis of complex phenotypes, with particular interest in human disease, variation in drug/treatment response, and disease outcomes. Current projects primarily focus on incorporating environmental context into medical genetics.
Dr. Arnaout’s lab is currently developing computational methods to bring precision phenotyping to echocardiography, and also using the zebrafish animal model to study cardiovascular developmental gene function and to model human cardiovascular disease.
The Grinberg Lab processes whole human brains for state-of-the-art quantitative histological analysis, digitize all of the results, and precisely registers to MRI. They are developing advanced tools for analysis of microscopic images that enable more comprehensive and higher-throughput studies of human brain tissue.
Dr. Brown uses knowledge engineering, health informatics, comparative-effectiveness research, semantic harmonization, and integration of datasets (including EHR) to examine health disparities and develop patient-centered health information tools.
The lab seeks to discover new therapeutic approaches to target the genetic mutations and altered signaling networks that are specific to cancer cells. Using functional genomics applied to mouse and human systems, we work to understand the transcriptional networks that regulate the outcome of specific oncogenic mutations and to understand how cancers become resistant to chemotherapy. This work relies heavily on computational genomic analysis, generating and using high-throughput datasets and next-generation sequencing for gene and network discovery. Our primary disease focus is lung cancer and pediatric sarcomas.
Dr. Kober uses ‘omics data (i.e., genotype and expression arrays, DNAseq — genome, exome, RNAseq, methylation arrays) to improve our understanding of the molecular mechanisms underlying common symptoms (e.g., fatigue, pain) or treatment failure experienced by patients with chronic medical conditions (e.g., cancer, HIV infection).
Dr. Tosun develops new algorithmic approaches for processing and analysis of multi-disciplinary/modal data including neuroimages, genetics, proteomics, as well as cognitive functioning measures in a unified framework. The primary aim is to identify multi-disciplinary/modality biomarkers for detecting the changes associated with disease specific neuropathology, improving understanding of pathophysiological progression and potentially providing a means of monitoring the efficacy and regional specificity of drug therapy for neurodegenerative diseases.
Dr. Majumdar’s research work on imaging, particularly magnetic resonance and micro computed tomography, and development of image processing and analysis tools, has been focused in the areas of osteoporosis, osteo-arthritis and lower back pain. Her research is diverse, ranging from technical development to clinical trials.
Dr. Nagarajan has multiple research interests, including understanding human brain plasticity associated with learning and disease, and determining neural mechanisms of controlling speech. He focuses on the development and refinement of multimodal structural and functional brain imaging and brain computer interfaces, for diagnosis and assessment in various patient populations. His current translational research program includes conducting multimodal brain imaging studies in people with Autism, Dementia, Tinnitus, Brain Tumors, Epilepsy, Traumatic Brain Injury, Stroke and Voice Disorders.
Dr. Lupo is focused on developing novel methods for acquisition, reconstruction, post-processing, and quantitative analysis of magnetic resonance brain images. Using a combination of multiparametric structural, physiological, and metabolic MRI techniques, her goal is to quantitatively characterize heterogeneity within malignant brain tumors, monitor response to novel treatment regimens, and investigate the long-term effects of therapy on healthy brain tissue structure and cognitive function. Many of the methodologies we develop initially to evaluate patients with brain tumors are also being applied to other neurological diseases.
Dr. Xu’s research focuses on investigating new MRI techniques with primary applications in pediatric neuroradiology. Another research focus is the development of new techniques on ultrahigh field MR scanners for small animal imaging, both in vivo and ex vivo. Techniques include high resolution MR anatomic, diffusion, and spectroscopy are being developed in collaboration with various colleagues in Neurodevelopment Biology, Neurology, Pediatrics, Neonatology, and Physiology.
Dr. Lazar is working to develop an analysis framework and software tools to help understand how patient characteristics interact with dental treatments in order to improve treatment decisions for individual patients and develop targeted treatments to reduce oral health disparities.
Dr. Blum is a cardiologist who specializes in the care of patients with congestive heart failure, valvular heart disease and preventative cardiology. He is dedicated to the early detection of heart disease and prevention through a heart-healthy lifestyle that includes diet, exercise and stress reduction. He has a special research interest in clinical decision support technology, social media and collaborative workspaces and their impact on the quality, effectiveness, and cost of care delivery.
Dr. Gansky’s research concentrates on oral health, health disparities, applied statistical analyses and related methodological issues. Balancing these components is essential to successful and practical population health research. Methodological examination helps ground health research and build convincing arguments, while collaborative health research generates opportunities for innovative statistical practice and provides challenges for developing ways to solve real world problems.
Dr. Sim’s group works to create an open software architecture that provides shared analysis, data presentation, and evaluation modules to support systematic and shared learning in mobile health. She also leads international efforts to build a single global portal for sharing individual participant-level data from clinical trials.
The Sirota lab develops incremental computational methods in the context of disease diagnostics and therapeutics – especially leveraging ‘omics and clinical data to better understand the role of the immune system.
The Butte lab builds tools in translational bioinformatics to make sense of big ‘omics and clinical data and solve new classes of problems in Oncology.
